Healthcare Equipment and Supplies
Company Overview of Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a medical technology company, focuses on the design, development, and commercialization of glucose monitoring systems for people with diabetes. Its first generation continuous glucose monitoring system, Eversense measures glucose levels in people with diabetes for a period of up to 90 days. The company was founded in 1996 and is headquartered in Germantown, Maryland.
20451 Seneca Meadows Parkway
Germantown, MD 20876
Founded in 1996
Key Executives for Senseonics Holdings, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $365.8K
Chief Financial Officer, Secretary and Treasurer
Total Annual Compensation: $286.7K
Vice President of Operations, Quality and Regulatory
Total Annual Compensation: $223.0K
Vice President of Global Sales and Marketing
Total Annual Compensation: $221.5K
Compensation as of Fiscal Year 2015.
Senseonics Holdings, Inc. Key Developments
Senseonics Holdings, Inc. Appoints Steven Edelman to its Board of Directors
Sep 6 16
Senseonics Holdings, Inc. announced that Steven Edelman, MD, clinical professor of medicine at the University of California San Diego-Veterans Affairs Healthcare System, has been appointed to its Board of Directors, effective September 2, 2016. Dr. Edelman is a clinical professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego and the Veterans Affairs Healthcare System of San Diego and the director of the Diabetes Care Clinic VA Medical Center. His research concentrates on developing, testing, and evaluating new technologies and pharmaceutical agents for the treatment of type 1 and type 2 diabetes, with a focus that includes glucose sensing technologies, clinical utilization of continuous glucose monitoring and effective use of anti-diabetic agents.
Senseonics Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
Aug 9 16
Senseonics Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. Net loss was $11.9 million, or $0.13 per basic and diluted share, in the second quarter of 2016, compared to $7.2 million, or $3.68 per basic and diluted share, in the second quarter of 2015. Revenue was $0.02 million against $0.023 million reported last year. Operating loss was $11.55 million against $6.9 million reported last year.
For the six months, the company reported net loss of $23.1 million or $0.27 per basic and diluted share on revenue of $0.02 million compared to net loss of $12.9 million or $6.63 per basic and diluted share on revenue of $0.04 million reported in the same period last year. Operating loss was $22.5 million against $12.3 million reported last year.
Senseonics Holdings, Inc. Reports Accuracy Results from U.S. Pivotal Study of Eversense CGM System
Aug 9 16
Senseonics Holdings, Inc. announced results of the PRECISE II (A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor) Clinical Investigation. Results from the 90 adults with diabetes generated over 16,000 comparative glucose data points and demonstrated strong accuracy for the 90-day continuous wear period with a mean absolute relative difference (MARD) of 8.8% across the 40-400 mg/dL range when compared to YSI blood reference values. The PRECISE II U.S. investigational device exemption trial enrolled 90 participants at eight clinical centers. The objective of the study was to determine the safety and effectiveness of the Eversense® CGM system over 90 days of continuous glucose sensor wear. Participants in the study underwent unilateral (n=75) or bilateral sensor (n=15) insertions in the clinic and used the system’s smart transmitter and mobile app at home for the next 90 days. Sensor glucose readings were calculated prospectively. Calibration with a standard home blood glucose meter was performed twice a day but real-time glucose readings and trends were not made available to participants. Clinic visits were scheduled at approximately 30-day intervals in order to obtain lab reference glucose values for comparison with the sensor values and to evaluate hyperglycemic and hypoglycemic challenges in a controlled setting.
Similar Private Companies By Industry
Recent Private Companies Transactions